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Abstract. although diabetes can be managed clinically with 
the use of insulin injections, it remains an incurable and 
inconvenient disorder. in the long-term, it is associated with 
a number of clinical complications, such as cardiovascular 
disease, resulting in a desire for the development of new 
methodologies to replace defective cells and provide a lasting 
normality without the need for drug treatment. Stem cells, 
including induced pluripotent stem cells, offer the possibility 
of generating cells suitable for transplantation due to their 
capacity to differentiate into all tissue lineages. however, 
many issues must be addressed before this type of treatment 
becomes a reality, including the need for a greater under-
standing of the underlying biology involved in the onset of 
diabetes.
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1. Stem cells and diabetes
current therapy for diabetes mellitus (dm) only provides 
limited protection against the late complications of diabetes; 
additionally, although it permits a relatively normal lifestyle, 
it is by no means a cure. it is crucial that novel therapies are 
developed that allow effective cell replacement to restore 
the normal physiological insulin secretion of patients and to 
eliminate the need for repeated invasive monitoring and exog-
enous insulin administration by injection.
For some time, dm has been considered a potential candi-
date disease for medical cellular therapeutic intervention via 
the replacement of defective β-cells (1). the source of these 
new β-cells includes the potential use of cells differentiated 
from human embryonic stem (hES) cell lines. hES cells are 
isolated from the inner cell mass of developing human blas-
tocysts sourced from excess embryos produced as a result of 
in vitro fertilisation (2). these cells are immortal, capable of 
unlimited	self-renewal,	and	therefore	offer	an	infinite	supply	
of scalable cells for transplantation. as these cells possess the 
ability to differentiate into cells from all three germ layers, 
they have the potential to generate all cell types from all 
tissues of the body. 
however, there are concerns regarding the use of hES 
cells as a tool for therapeutic transplantation. First, there are 
ethical concerns inherent in the use and disposal of human 
embryos (3). this has caused heated debate and regulation 
over the use of these cells. Second, hES cells themselves are 
inherently tumourigenic, giving rise to teratoma formation in 
animal models (4). any cells for transplantation differenti-
ated from these cells would therefore need to be completely 
free of any hES cells from which they were derived. Finally, 
differences in major and minor histo-compatibility complexes 
(mhcs) present as antigens on any form of graft tissue cells 
may trigger an immune response from the host, resulting in 
the rejection of the graft. although self-renewing hES cells 
generally express low levels of mhc antigens (5), these levels 
are gradually up-regulated during their subsequent differ-
entiation	 into	 specific	 tissue	 cell	 types,	 leading	 to	 concerns	
about the possibility of inducing graft vs. host responses from 
tissue derived from this type of cell. this may necessitate the 
creation	of	a	bank	of	qualified	and	histo-compatibility-typed	
hES cell lines for transplantation to address these issues (6). 
the ability to generate a supply of pluripotent stem cells 
directly from the somatic cells of affected individuals would 
provide the basis of autologous transplantation regimes. this 
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would avoid the risk of immune rejection or the requirement 
for long-term immunosuppressive therapies, as somatic cells 
from the patient's own body would be treated in a manner to 
create stem cells that resemble embryonic stem cells. these 
cells could subsequently be differentiated into the required 
tissue type (possibly after correction of any genetic defects) 
and used to treat the patient's defective tissue. in addition to 
avoiding graft vs. host reactions, this type of treatment would 
also circumvent many of the ethical concerns associated with 
the use of embryo-derived cell types. Several methods have 
been considered in order to induce somatic cells to revert to 
an embryonic state, making them suitable for further differ-
entiation. Strategies including nuclear transfer, cellular fusion 
and	 induced	 reprogramming	 with	 defined	 factors	 have	 all	
been employed. 
2. Nuclear transfer techniques for patient-specific stem cells
Nuclear	 transfer	 was	 first	 described	 in	 1952	 by	 Briggs	 and	
King, (7) who demonstrated the creation of normal hatched 
Rana Pipiens tadpoles following the transfer of nuclei from 
blastocysts into enucleated eggs. although many examples of 
successful embryonic nuclear transfer have been reported, it 
proved	 difficult	 to	 successfully	 accomplish	 nuclear	 transfer	
from a differentiated mammalian adult cell. a major break-
through was accomplished by the Wilmut group in 1996, with 
the creation of ‘dolly the sheep’ from nuclei derived from 
cultured adult mammary gland cells (8). Further mammals 
have since been successfully cloned, including mice, cows, 
goats, pigs, rabbits and cats (9). While the production of adult 
animals	 from	 this	method	 remains	 somewhat	 inefficient,	 by	
contrast the frequency of the derivation of mouse ES cells 
from blastocysts created by nuclear transfer appears similar 
to that of ES derivation from natural conceptus (10). this has 
led	 to	 the	 theoretical	possibility	of	creating	‘patient-specific’	
ES cells through the transfer of a somatic cell nucleus from 
a patient into a human oocyte. although breakthroughs in 
this area have been reported and retracted, nuclear transfer 
remains an active area of stem cell therapeutic research (16). 
the main obstacle to using nuclear transfer to generate 
‘patient-specific’	ES	cells	is	the	limitation	associated	with	the	
access to donated human oocytes. an alternative approach 
that has been considered is reprogramming via the fusion of 
somatic cells with previously isolated hES cells. this rationale 
is an extension of that involved with standard cloning, but in 
this	case	via	the	use	of	an	existing	hES	cell.	The	first	demon-
stration of this technique involving human ES cells was in 
2005 by cowan et al (11), who demonstrated that the fusion of 
human	fibroblasts	with	hES	cells	resulted	in	hybrid	cells	with	
similar morphology, growth rates and antigenic expression to 
hES	cells.	The	original	fibroblasts	were	marked	with	antibiotic	
resistance genes via retroviral transduction in order to allow 
easy selection of any resultant hybrid cells. the hybrid cells 
were found to be tetraploid containing both somatic and hES 
cell chromosomes. the main limitation of the therapeutic use 
of these cells is thus due to the continued presence of hES 
chromosomes. this issue has been addressed to a degree by 
the	 development	 of	 techniques	 to	 eliminate	 specific	 chro-
mosomes from the resultant hybrid cells. matsumura et al 
demonstrated	 such	 a	 technique	with	 the	 removal	 of	 specific	
ES cell-derived chromosomes from fused hybrid cells using 
genetic targeting techniques (12).
there remains much work to be accomplished on ES 
cell fusion techniques if this technique is to provide a viable 
clinical resource. there is a strong possibility of rejection 
following transplantation of tissues generated from these cells 
due to persistent expression of ES cell antigens in the resultant 
hybrid cells (13). improved techniques capable of removing 
the entire complement of ES cell chromosomes and avoiding 
recombination between host and transferred chromosomes are 
required.
3. iPS cells – cellular reprogramming by defined factors
it has long been hypothesized that ES cells may contain 
specific	 and	 dominant	 genes	 or	 factors	 that	 enable	 them	 to	
self renew and maintain their pluripotent state. indeed, the 
ES fusion techniques listed above support this hypothesis, 
as ES cell/somatic cell fusion results in cells that maintain 
a pluripotent phenotype via the reprogramming of somatic 
chromosomes (14). proceeding from this hypothesis, it was 
considered possible to induce and maintain pluripotency by 
the	introduction	or	activation	of	specific	factors	within	somatic	
cells.	The	first	groundbreaking	study	that	employed	this	theory	
was published in 2006 by takahashi and yamanaka (15). in 
this study, the group systematically overexpressed genes in 
mouse	embryonic	fibroblasts	(MEFs)	 that	were	known	to	be	
expressed in ES cells in order to assess their ability to induce 
pluripotency. an assay based on the expression of drug resis-
tance	linked	to	the	expression	of	the	Fbx15	gene	(an	identifier	
of stem cell pluripotency) was used to assess the effects of 
each	of	the	factors	when	introduced	to	the	fibroblasts	by	retro-
viral transduction. no single factor was capable of inducing 
pluripotency. however, when pooled, the overexpression 
of these genes led to the production of multiple ES-like cell 
colonies. by a gradual reduction in the number of factors 
used, four factors were ultimately determined to be the key 
modulators involved in the reprogramming of these ES-like 
cells. these genes were oct3/4, Klf4, Sox2 and cmyc. the 
resultant ES-like cells were designated ‘induced pluripotent 
stem’ (ipS) cells. these ipS cells were analysed by rt-pcr 
and dna microarray studies in order to compare marker gene 
expression,	and	were	found	to	express	the	majority	of	specific	
ES cell marker genes. recent evidence does suggest a degree 
of difference between ipS and ES cells at the transcriptional 
level (16), and there is some evidence of retention of somatic 
gene expression from the source cell type (17). the pluripo-
tency	 of	 these	 cells	 was	 confirmed	 by	 their	 ability	 to	 form	
teratomas, where the cells differentiated into all three germ 
layers, with evidence of neural tissue, cartilage and columnar 
epithelium. however, an inability of the created mouse ipS 
cells to produce adult chimera mice and subsequent germline 
transmission led to concerns that the cells were not fully 
reprogrammed. 
in 2007, three groups generated ipS cells that were capable 
of generating both adult and germline chimeras (18-20). these 
groups used oct4 and nanog activation to select for pluripo-
tency, which resulted in cells that were both epigenetically 
and biologically indistinguishable from normal ES cells. 
the meissner method (18) involved selecting colonies based 
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upon	cell	morphology	and	eGreen	fluorescent	protein	(eGFP)	
expression instead of using drug resistance as in the takahashi 
model (15). meissner et al also demonstrated the creation 
of	 an	 iPS	 cell	 line	 from	 genetically	 unmodified	 mice	 that	
was capable of generating chimeric mice. Wernig et al used 
mouse	embryonic	fibroblasts	carrying	a	neomycin	resistance	
marker present in either the endogenous oct4 or nanog (20). 
this group also demonstrated that, although pluripotency is 
initially established by virally transduced factors, this pluri-
potency is mainly maintained by the activity of endogenous 
pluripotency factors as the viral factors are largely silenced 
by de novo methylation. okita et al (19) demonstrated ipS cell 
generation using the four retroviral factors following selection 
for nanog. as with the other groups, these cell colonies were 
capable of generating adult chimera mice and were trans-
mitted through the germline. approximately 20% of the adult 
chimeras formed from these cells developed tumours, possibly 
due to the reactivation of the c-myc retroviral transgene. this 
propensity would obviously limit the potential clinical appli-
cations if the above methods were used to generate ipS cells 
to be differentiated into transplantable cells.
Soon after the above studies, ipS cells were again gener-
ated	 from	 human	 fibroblasts	 by	 Takahashi	 and	 Yamanaka	
using the same four factors and a retroviral transduction 
method in order to induce pluripotency in adult human dermal 
fibroblasts	(21).	In	this	case,	to	increase	the	transduction	effi-
ciency, the mouse retroviral receptor Slc7a1 was introduced 
into	 the	 fibroblasts	 via	 a	 lentiviral	 vector	 prior	 to	 retroviral	
induction with the four factors. this resulted in the formation 
of ES-like cell colonies at day 30. the human ipS cells created 
in this way were morphologically similar to hES cells and had 
similar surface markers, gene expression, telomerase activity, 
in vitro differentiation and teratoma formation. there was 
evidence that the retrovirus expression was strongly silenced 
following transduction, however, there also was evidence of 
at least 20 retroviral integration sites per clone (approximately 
three to six for each factor introduced). park et al (22) induced 
iPS	cells	from	human	ES	cell-derived	fetal	fibroblasts	(in	this	
case differentiated ES cells expressing GFp and neomycin 
resistance genes integrated into the oct4 locus). the cells 
were infected with a cocktail of retroviral supernatants from 
the four factors. Following this, they generated ipS cells from 
primary	fetal	tissue	as	well	as	adult	fibroblasts.	In	these	studies,	
oct4 and Sox2 appeared to be essential for reprogramming 
with	either	KLF4	or	cMyc	enhancing	the	efficiency	of	colony	
formation. yu et al (23) also successfully demonstrated the 
reprogramming of human somatic cells to pluripotency, but 
accomplished this by using oct4, Sox2, nanog and lin28. 
therefore, oct4 and Sox2 appear to play a pivotal role 
in the generation of ipS cells, with other factors being inter-
changeable. huangfu et al (24) successfully generated ipS cells 
from	primary	human	fibroblasts	using	retroviruses	expressing	
only oct4 and Sox2 in an optimized protocol exposing the 
cells to valproic acid (a histone deacetylase inhibitor shown to 
improve	reprogramming	efficiency	in	MEFs).	This	has	poten-
tial clinical application advantages due to the elimination of 
two potent oncogenes from the transduction process. in 2009, 
Kim et al (25) demonstrated single factor induction of ipS 
cells by using only oct4. in this case, adult mouse neural stem 
cells were used as the source cell type. currently, single factor 
induction has not yet been reported in human cells, although 
this certainly will be a major area of research.
other reprogramming methods have been successfully 
implemented following the original retroviral methods. Virus-
based reprogramming methods result in varying degrees of 
viral integration into the somatic genome. this obviously 
carries with it safety concerns over endogenous gene activation 
or inactivation as well as transgene persistence or reactiva-
tion after differentiation. a single ipS clone has 20-40 viral 
integration sites, and although it may be possible to perform 
whole-genome sequencing to map these sites, it would prove 
difficult	to	ensure	their	clinical	safety	(26).	
Since the initial retroviral-mediated generation of ipS cells, 
several groups have successfully employed other methods of 
reprogramming somatic cells to the pluripotent state, including 
plasmids (27), lentiviruses (28), excisable transgenes (29,30), 
recombinant proteins (31) and episomes (32). 
ipS cells created by plasmid transfection have been 
reported by okita et al (27). in this report, the group used two 
individual plasmid vectors containing the caG promoter, with 
one containing oct4, Klf4 and Sox2 and the other containing 
cMyc.	Using	a	transfection	protocol	targeting	embryonic	fibro-
blasts on days 1, 3, 5 and 7, they successfully created mouse 
ipS cells, with no evidence of the genomic integration of 
plasmid dna. these clones successfully generated teratomas 
and chimeric mice. Soldner et al (28) made use of doxycycline-
inducible lentiviral vectors of the four reprogramming factors, 
which were excisable with cre-recombinase. by this method, a 
total of 16 clones were generated, with no evidence of integra-
tion of any of the viral reprogramming factors. 
recently, two groups have used excisable transgene tech-
nology to allow virus-free integration of the programming 
factors, followed by their subsequent removal (29,30). both 
groups made use of the 2a peptide sequence from foot and 
mouth disease virus to link the sequences of cmyc, Klf4, oct4 
and	Sox2,	 allowing	 efficient	multiprotein	 expression	 from	 a	
single vector. transduction to the pluripotent stem cell state 
was	 first	 achieved	 by	 introduction	 of	 the	 single	 vector	 2A	
linked system. the exogenous factors were then removed by 
transient cre transfection, as the reprogramming cassette was 
flanked	by	loxP	sites.	A	piggyBac	(PB)	transposon	was	then	
used to deliver the reprogramming factors under the control of 
a doxycycline-inducible system. the pb system allows for the 
removal of the transgene upon re-expression of the pb trans-
posase, thus creating ipS cells with no trace of reprogramming 
factors once the exogenous expression is no longer required. 
Zhou et al (31) recently described the generation of 
mouse ipS cells using recombinant proteins. this technique 
avoids the use of any genetic material, potentially reducing 
the	 likelihood	 of	 unexpected	 genetic	 modifications	 to	 the	
somatic genome. in this case, the reprogramming proteins 
are delivered directly into the cell, as opposed to relying on 
the cell machinery to transcribe the proteins itself. this study 
used E. coli bacteria to generate inclusion bodies containing 
the	proteins,	which	were	subsequently	purified.	The	resultant	
proteins were then used to reprogram mEFs, resulting in 
induced pluripotent stem cells. there are potential advantages 
to this technique, as there is no need to analyse and select the 
resultant colonies based upon the existence of integration sites 
in the somatic genome.
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it has also recently been reported that certain small mole-
cules can be used to both enhance the reprogramming process 
and,	in	some	cases,	to	replace	specific	factors.	Shi	et al (33,34) 
identified	 small	 molecule	 combinations	 that	 significantly	
enhance the reprogramming process (using only oct4/Klf4) 
in	MEFs.	Other	groups	have	also	shown	enhanced	efficiency	
with the additional use of small molecules that are known 
to	 inhibit	 specific	pathways	within	 the	cell	 (24,35).	There	 is	
also a desire to carry out ipS generation using small molecule 
techniques alone.
The	final	method	 employed	 for	 the	generation	of	 human	
ipS cells completely devoid of vector and transgene sequences 
has been the use of episomal vectors based on the Ebna1/
orip vector, which is derived from the Epstein-barr virus 
(32). these vectors are gradually lost from proliferating cells, 
resulting in a fraction of subclones showing a complete absence 
of both vector and transgene sequences. although this method 
currently results in relatively low reprogramming frequencies, 
this will likely be improved by the addition of other chemical 
compounds	and	small	molecules	shown	to	increase	efficiency	
with the other modalities.
4. Generation of β-cells from iPS cells
ES cells have the ability to generate cells of any tissue type. 
this makes them candidates for creating functional β-cells, 
which could potentially be used as a transplantable tissue 
source for diabetic patients. initial attempts at this type of 
differentiation using mouse ES cells used a transfection 
and selection method to screen for insulin-secreting ES cell 
clones capable of restoring normoglycaemia in diabetic mouse 
models (36). lumelsky et al (37) selected cells positive for 
nestin	(a	filament	protein	found	in	neural	precursors)	following	
embryoid body formation. Following further differentiation, 
cells that resembled islet cells were produced. however, 
repeated analysis of such protocols by other groups suggested 
that these cells were not capable of de novo insulin synthesis 
to the same degree as normal β-cells, and in fact were princi-
pally secreting insulin absorbed from the culture media.
it became clear that a more stepwise approach to β-cell 
generation	 was	 required,	 capable	 of	 reflecting	 the	 changes	
observed in normal human development. in these protocols, the 
initial differentiation step is designed to drive differentiation 
towards	the	formation	of	definitive	endoderm.	Developmental	
studies have revealed that the formation of endoderm during 
normal fetal development is instigated by nodal (a member 
of the transforming growth factor-β). using activin a, which 
is closely related to nodal, two groups successfully generated 
endodermal cells (38,39). Following this, one of these groups 
continued with a stepwise differentiation protocol, based on 
normal	 development	 through	 definitive	 endoderm,	 primitive	
gut tube, posterior foregut, pancreatic precursor and endocrine 
cells (40). the cells generated by this protocol contained 
similar amounts of glucose to normal adult β-cells. When 
exposed to secretory stimuli, these cells were also capable 
of releasing insulin. however, the lack of response of these 
cells to glucose suggested that they may be akin to immature 
fetal β-cells rather than mature β-cells found in the adult. in 
2007, Jiang et al continued to develop a step-wise approach 
from	 definitive	 endoderm	 in	 serum-free	 conditions	 (41).	
this protocol resulted in the production of insulin-producing 
islet-like clusters containing cells representative of ductal, 
exocrine and endocrine pancreas. these β-like cells contained 
secretory granules and responded to an in vitro glucose-
stimulated release assay. in 2008, Kroon et al successfully 
generated human endoderm capable of producing insulin 
that was responsive to glucose in such a way as to achieve 
normoglycaemia in a diabetic mouse model (1). in this case, 
the endoderm was implanted into mice prior to terminal β-cell 
differentiation. these mice were then rendered diabetic by the 
destruction of their natural β-cells. animals with the grafted 
endoderm maintained normal blood glucose levels, while 
control animals became hyperglycaemic. When the grafts 
were removed, the grafted animals were also rendered hyperg-
lycaemic. although this research is extremely promising, over 
15% of the animals developed tumours in the graft, raising 
safety concerns for translation in humans.
currently, there are two successful reports of insulin-
producing cells generated from ipS cells (42,43). tateishi et al 
(42) used retrovirally induced ipS cells sourced from human 
skin cells. these cells were then subjected to a protocol 
almost identical to that of Jiang et al (41) above. this resulted 
in the formation of glucose-sensitive insulin-secreting cells. 
Following this, Zhang et al (43) published a protocol similar 
to Jiang et al to differentiate ES and ipS cells in a step-wise 
fashion, resulting in approximately 25% of cells positive for 
insulin. these cells secreted c-peptide in response to glucose 
stimulation in vitro. maehr et al (44) also demonstrated the 
generation of ipS cells from the skin biopsies of patients with 
type 1 dm, with subsequent differentiation of these cells into 
insulin-producing/glucose-responsive cells. 
5. Future directions
Significant	 steps	 have	 been	 made	 towards	 the	 use	 of	 stem	
cell technologies to generate β-cells as a potential therapy 
for patients suffering from diabetes. however, many hurdles 
must be overcome to generate a safe clinical application 
from this technology. ipS cell technology may provide the 
potential for ethically acceptable replacement tissue that is 
free from the problem of immunological-mediated rejection. 
Studies demonstrate that ipS cells clearly have the potential 
to differentiate into β-cells,	 although	 better	 and	 more	 effi-
cient techniques, as well as more robust and more extensive 
characterisation of the differentiated cells, must be addressed. 
despite these advances, the possibility of tumour formation 
caused from contaminating residual stem cells after differen-
tiation that may lead to teratoma formation remains a concern. 
moreover, the inherent risk of aberrations caused by repro-
gramming must be carefully studied. if retroviral integration 
is used, then there are concerns about the effects of these inte-
grations on the host genome, as well as the use of oncogenic 
viruses. to this end, even greater importance will be placed 
on studies to develop safer methodologies of reprogramming, 
which are already well underway. this rapidly developing ipS 
technology	offers	a	promising	route	for	finding	a	cure	for	this	
widespread, costly, and eventually destructive disease. clearly, 
this approach must be coupled with endeavours to obtain a 
comprehensive understanding of the factors responsible for 
the onset of diabetes in any particular patient. Even when 
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β-cells	for	transplantation	can	be	efficiently	constructed	from	
stem cells, a greater understanding is required concerning 
both autoimmune reactions that lead to β-cell destruction and 
those inherent β-cell defects that lead to reduced functionality 
in order for this technology to be applied.
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